普莱柯生物工程股份有限公司2025年年度业绩预告

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., forecasts a significant increase in net profit for the year 2025, with expectations of a rise between 89.64% and 110.11% compared to the previous year [2][3]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company to be between 176 million to 195 million yuan for 2025, representing an increase of 83.19 million to 102.19 million yuan year-on-year [2][3]. - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 137 million to 153 million yuan, reflecting a year-on-year increase of 70.19% to 90.07% [2][3]. Group 2: Previous Year’s Performance - In the previous year, the net profit attributable to shareholders of the parent company was 92.81 million yuan, and the net profit after excluding non-recurring gains and losses was 80.50 million yuan [5]. Group 3: Reasons for Performance Increase - The introduction of new products, such as the avian adenovirus series vaccine, has contributed to the company's growth. Additionally, the pet sector has seen rapid development through enhanced channel building and brand development [7]. - The company is focusing on marketing system reforms, controlling sales expenses, and optimizing production processes and procurement management to reduce production costs, demonstrating strong operational resilience [7].